5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019

Source: https://www.researchbymarkets.com/report/5-nucleotidase-ecto-5-nucleotidase-or-cd73-or-nt5e-or-ec-3135-pipeline-review-h1-2019-268238.html

For queries regarding this report: https://www.researchbymarkets.com/sample-request/268238

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Therapeutic Products under Development, Key Players in 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Therapeutics, 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Pipeline Overview, 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Pipeline, 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Pipeline Assessment

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019

Summary

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5′ Nucleotidase – Pipeline Review, H1 2019, outlays comprehensive information on the 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5’nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.

Furthermore, this report also reviews key players involved in 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
– The report reviews 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
– The report assesses 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned:
Arcus Biosciences Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec AG
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
MedImmune LLC
Novartis AG
Oric Pharmaceuticals Inc
Peloton Therapeutics Inc
Selvita SA

Contact Us:

ResearchByMarkets.com

Ritesh Tiwari, Director

enquiry@researchbymarkets.com

USA: +1-800-416-3124

https://www.researchbymarkets.com/aboutus

Follow us on Social Media:

Facebook: https://www.facebook.com/researchbymarkets/

LinkedIn: https://www.linkedin.com/company/researchbymarkets/

Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.